Akkermansia muciniphila is a bacterium that lives in the mucus lining of your intestines, where it makes up roughly 1 to 3% of the total gut microbiome in healthy adults. It feeds on mucus, and that seemingly destructive habit turns out to be one of its most important features: by consuming old mucus, it signals your gut to produce a fresh, healthy layer. This cycle helps maintain the barrier between your intestines and your bloodstream, and a growing body of research links higher levels of this bacterium to better metabolic health, stronger immune function, and even improved responses to certain cancer treatments.
Basic Biology
Akkermansia muciniphila belongs to the phylum Verrucomicrobia, making it something of an oddball in the gut. Most well-known gut bacteria fall into two dominant groups (Firmicutes and Bacteroidetes), so Akkermansia occupies its own distinct branch of the microbial family tree. It is Gram-negative, meaning it has an outer membrane in addition to its cell wall, and it is a strict anaerobe that thrives in the oxygen-free environment deep within the intestinal mucus layer.
Its name tells you what it does: “muciniphila” means “mucin-loving.” Mucin is the protein that gives mucus its gel-like consistency, and Akkermansia produces specialized enzymes that can break apart the complex sugar chains decorating mucin molecules. It clips off sugar residues one by one, first removing the outermost sugars (like sialic acid and fucose), then working its way to the core structure. This enzymatic toolkit is encoded across multiple genes, giving Akkermansia a highly specialized ability that relatively few gut microbes share.
How It Strengthens the Gut Barrier
Eating mucus sounds counterproductive, but the process actually triggers goblet cells in the intestinal lining to ramp up production of fresh mucin. The result is a constantly renewed mucus layer that serves as a physical and chemical shield between gut bacteria and the cells of your intestinal wall.
Akkermansia also releases tiny particles called extracellular vesicles that directly influence gut barrier integrity. In lab studies, these vesicles increased the production of occludin, a key protein that forms the tight junctions sealing intestinal cells together. Tighter junctions mean fewer gaps for bacterial toxins and inflammatory molecules to slip through into the bloodstream. In mice fed a high-fat diet, treatment with these vesicles reduced weight gain and improved blood sugar control, effects tied to that same tightening of the gut barrier. The mechanism works through an energy-sensing pathway inside cells (AMPK), which Akkermansia’s vesicles activate like a switch.
Metabolic Health Effects
People with obesity tend to carry less Akkermansia. Data from the American Gut Project found that participants with a normal BMI had a median relative abundance of 0.088%, while those with obesity had roughly half that at 0.043%. Interestingly, people who were overweight but not obese showed levels statistically similar to the normal-weight group, suggesting that a meaningful drop in Akkermansia is more closely tied to significant metabolic disruption than to modest weight differences alone.
One of the most intriguing discoveries is a protein secreted by Akkermansia, known as P9, that stimulates the release of GLP-1, a hormone your gut produces after eating. GLP-1 slows digestion, signals fullness, and helps regulate blood sugar. It’s the same hormone that medications like semaglutide (the active ingredient in Ozempic and Wegovy) are designed to mimic. Another protein on Akkermansia’s outer membrane, called Amuc_1100, has been shown to partially replicate the bacterium’s metabolic benefits on its own, pointing to specific molecules rather than the whole organism as drivers of health effects.
Clinical Trial Results
A proof-of-concept clinical trial tested daily Akkermansia supplements in overweight and obese volunteers over three months. Participants received either live bacteria, heat-treated (pasteurized) bacteria, or a placebo. Both forms were safe and well tolerated, but the pasteurized version outperformed the live one on several measures. Compared to placebo, the pasteurized form improved insulin sensitivity by about 29%, reduced circulating insulin levels by 34%, and lowered total cholesterol by roughly 9%.
Weight-related changes from the pasteurized supplement were more modest and didn’t quite reach statistical significance: an average loss of 2.27 kg in body weight, 1.37 kg in fat mass, and 2.63 cm in hip circumference compared to baseline. These trends are encouraging but would need larger trials to confirm. The surprising superiority of the pasteurized form likely traces back to Amuc_1100, a heat-stable protein on the bacterium’s surface that remains active even after the organism itself is no longer alive.
Akkermansia and Cancer Immunotherapy
Some of the most striking research connects Akkermansia levels to how well cancer patients respond to checkpoint immunotherapy, particularly PD-1 blockers used in lung cancer. In a study of advanced non-small-cell lung cancer patients, those who had detectable Akkermansia in their gut (the Akk+ group) had an objective response rate of 28%, compared to 18% in those without it. Among patients receiving immunotherapy as their first-line treatment, the gap widened: 41% responded in the Akk+ group versus 19% in the Akk- group.
Survival differences were similarly notable. Median overall survival was 18.8 months for Akk+ patients compared to 15.4 months for Akk- patients. Among first-line immunotherapy patients, 59% of those with Akkermansia were still alive at 12 months, compared to 35% without it. However, the relationship isn’t simply “more is better.” Patients with extremely high levels of Akkermansia (above the 77th percentile) actually had worse outcomes, with a median survival of just 7.8 months compared to 27.2 months for those with moderate levels. This U-shaped pattern suggests that balance matters: a healthy presence is beneficial, but an overgrowth may signal underlying gut dysfunction.
Foods That Support Akkermansia Growth
You can’t eat Akkermansia directly through food, but certain dietary compounds encourage its growth in your gut. Polyphenols, the antioxidant compounds abundant in deeply colored fruits, are the strongest candidates. Grape polyphenols, cranberry extracts, and pomegranate have all been linked to increased Akkermansia levels in both animal and human studies.
In one mouse study comparing grape polyphenol extract to other antioxidants like vitamin C and beta-carotene, only the grape polyphenols triggered a significant Akkermansia bloom, with an average increase of 468% in relative abundance compared to baseline. The mechanism appears to involve polyphenols scavenging reactive oxygen species in the gut, creating a more favorable low-oxygen environment where Akkermansia thrives. This aligns with its biology as a strict anaerobe: anything that reduces oxygen in the gut interior gives it a competitive advantage.
Practically, this means regularly eating foods like grapes, blueberries, cranberries, pomegranates, and green tea may help foster a gut environment where Akkermansia can flourish. A high-fiber diet also supports the overall mucus layer that Akkermansia depends on, since fiber stimulates mucin production through other bacterial pathways.
Supplement Availability and Regulation
Akkermansia muciniphila supplements are commercially available in the United States, typically sold as pasteurized (heat-treated) formulations. The bacterium has been submitted to the FDA through the New Dietary Ingredient notification process, which requires manufacturers to demonstrate safety before marketing. In Europe, the European Food Safety Authority has evaluated pasteurized Akkermansia as a novel food ingredient. These regulatory pathways mean the supplements on the market have undergone safety review, though they are not approved as drugs and cannot legally claim to treat or prevent disease.
Most supplements provide around 10 billion cells per dose, matching the amount used in the clinical trial described above. Because the pasteurized form showed stronger metabolic effects than live bacteria in that trial, heat-treated products are the current standard. Live formulations present additional challenges, since Akkermansia is a strict anaerobe that dies quickly when exposed to oxygen, making shelf-stable live products difficult to manufacture reliably.